Published online 28 August 2006 doi:10.1084/jem.20060077
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 9, 2191-2200
The plasminogen activator system modulates sympathetic nerve function
Ulrich Schaefer1,
Takuji Machida1,
Sandra Vorlova2,
Sidney Strickland2, and
Roberto Levi1
1 Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021
2 Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY 10021
CORRESPONDENCE Roberto Levi: rlevi{at}med.cornell.edu
Sympathetic neurons synthesize and release tissue plasminogen activator (t-PA). We investigated whether t-PA modulates sympathetic activity. t-PA inhibition markedly reduced contraction of the guinea pig vas deferens to electrical field stimulation (EFS) and norepinephrine (NE) exocytosis from cardiac synaptosomes. Recombinant t-PA (rt-PA) induced exocytotic and carrier-mediated NE release from cardiac synaptosomes and cultured neuroblastoma cells; this was a plasmin-independent effect but was potentiated by a fibrinogen cleavage product. Notably, hearts from t-PAnull mice released much less NE upon EFS than their wild-type (WT) controls (i.e., a 76.5% decrease; P < 0.01), whereas hearts from plasminogen activator inhibitor-1 (PAI-1)null mice released much more NE (i.e., a 275% increase; P < 0.05). Furthermore, vasa deferentia from t-PAnull mice were hyporesponsive to EFS (P < 0.0001) but were normalized by the addition of rt-PA. In contrast, vasa from PAI-1null mice were much more responsive (P < 0.05). Coronary NE overflow from hearts subjected to ischemia/reperfusion was much smaller in t-PAnull than in WT control mice (P < 0.01). Furthermore, reperfusion arrhythmias were significantly reduced (P < 0.05) in t-PAnull hearts. Thus, t-PA enhances NE release from sympathetic nerves and contributes to cardiac arrhythmias in ischemia/reperfusion. Because the risk of arrhythmias and sudden cardiac death is increased in hyperadrenergic conditions, targeting the NE-releasing effect of t-PA may have valuable therapeutic potential.
Abbreviations used: CNBr-F, cyanogen bromidedigested fibrinogen; EFS, electrical field stimulation; EIPA, 5-(N-ethyl-N-isopropyl)-amiloride; KH, Krebs-Henseleit; NE, norepinephrine; NHE, Na+/H+ exchanger; PAI-1, plasminogen activator inhibitor-1; PVC, premature ventricular contraction; rPAI-1, recombinant PAI-1; rt-PA, recombinant t-PA; t-PA, tissue plasminogen activator; VF, ventricular fibrillation; VT, ventricular tachycardia.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Related Article
-
Sympathy for t-PA
- Heather L. Van Epps
J. Exp. Med. 2006 203: 2045b.
[Full Text]
[PDF]
This article has been cited by other articles:
-
Park, L., Gallo, E. F., Anrather, J., Wang, G., Norris, E. H., Paul, J., Strickland, S., Iadecola, C.
(2008). Key role of tissue plasminogen activator in neurovascular coupling. Proc. Natl. Acad. Sci. USA
105: 1073-1078
[Abstract]
[Full Text]
-
Schaefer, U., Machida, T., Broekman, M. J., Marcus, A. J., Levi, R.
(2007). Targeted Deletion of Ectonucleoside Triphosphate Diphosphohydrolase 1/CD39 Leads to Desensitization of Pre- and Postsynaptic Purinergic P2 Receptors. J. Pharmacol. Exp. Ther.
322: 1269-1277
[Abstract]
[Full Text]
-
Schaefer, U., Vorlova, S., Machida, T., Melchor, J. P., Strickland, S., Levi, R.
(2007). Modulation of Sympathetic Activity by Tissue Plasminogen Activator Is Independent of Plasminogen and Urokinase. J. Pharmacol. Exp. Ther.
322: 265-273
[Abstract]
[Full Text]